Cargando…
Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744190/ https://www.ncbi.nlm.nih.gov/pubmed/36518770 http://dx.doi.org/10.3389/fimmu.2022.1021481 |
_version_ | 1784848866478129152 |
---|---|
author | Masset, Christophe Dantal, Jacques Soulillou, Jean-Paul Walencik, Alexandre Delbos, Florent Brouard, Sophie Giral, Magali |
author_facet | Masset, Christophe Dantal, Jacques Soulillou, Jean-Paul Walencik, Alexandre Delbos, Florent Brouard, Sophie Giral, Magali |
author_sort | Masset, Christophe |
collection | PubMed |
description | Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomized trial evaluating CNI weaning in stable kidney transplant recipients without anti-HLA immunization. The trial was interrupted prematurely due to a high number of de novo DSA (dnDSA) and biopsy proven acute rejection (BPAR) in patients who underwent tacrolimus weaning, resulting in treatment for rejection and resumption of tacrolimus. We report here the long-term outcomes of patients included in this clinical trial. Ten years after randomization, all patients are alive with a functional allograft. They all receive tacrolimus therapy except one with recurrent cutaneous neoplasia issues. Long-term eGFR was comparable between patients of the two randomized groups (46.4 ml/min vs 42.8 ml/min). All dnDSA that occurred during the study period became non-detectable and all rejections episodes were reversed. The retrospective assessment of HLA DQ single molecule epitope mismatching determined that a majority of patients who developed dnDSA after tacrolimus withdrawal would have been considered at high immunological risk. Minimization of immunosuppression remains a challenging objective, mainly because of the issues to properly select very low immunological risk patients. Valuable improvements have been made the last decade regarding evaluation of the allograft rejection notably through the determination of numerous at-risk biomarkers. However, even if the impact of such tools still need to be clarify in clinical routine, they may permit an improvement in patients’ selection for immunosuppression minimization without increasing the risk of allograft rejection. |
format | Online Article Text |
id | pubmed-9744190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97441902022-12-13 Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients Masset, Christophe Dantal, Jacques Soulillou, Jean-Paul Walencik, Alexandre Delbos, Florent Brouard, Sophie Giral, Magali Front Immunol Immunology Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomized trial evaluating CNI weaning in stable kidney transplant recipients without anti-HLA immunization. The trial was interrupted prematurely due to a high number of de novo DSA (dnDSA) and biopsy proven acute rejection (BPAR) in patients who underwent tacrolimus weaning, resulting in treatment for rejection and resumption of tacrolimus. We report here the long-term outcomes of patients included in this clinical trial. Ten years after randomization, all patients are alive with a functional allograft. They all receive tacrolimus therapy except one with recurrent cutaneous neoplasia issues. Long-term eGFR was comparable between patients of the two randomized groups (46.4 ml/min vs 42.8 ml/min). All dnDSA that occurred during the study period became non-detectable and all rejections episodes were reversed. The retrospective assessment of HLA DQ single molecule epitope mismatching determined that a majority of patients who developed dnDSA after tacrolimus withdrawal would have been considered at high immunological risk. Minimization of immunosuppression remains a challenging objective, mainly because of the issues to properly select very low immunological risk patients. Valuable improvements have been made the last decade regarding evaluation of the allograft rejection notably through the determination of numerous at-risk biomarkers. However, even if the impact of such tools still need to be clarify in clinical routine, they may permit an improvement in patients’ selection for immunosuppression minimization without increasing the risk of allograft rejection. Frontiers Media S.A. 2022-11-28 /pmc/articles/PMC9744190/ /pubmed/36518770 http://dx.doi.org/10.3389/fimmu.2022.1021481 Text en Copyright © 2022 Masset, Dantal, Soulillou, Walencik, Delbos, Brouard, Giral and the Nantes DIVAT Consortium https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Masset, Christophe Dantal, Jacques Soulillou, Jean-Paul Walencik, Alexandre Delbos, Florent Brouard, Sophie Giral, Magali Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title | Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title_full | Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title_fullStr | Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title_full_unstemmed | Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title_short | Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
title_sort | case report: long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744190/ https://www.ncbi.nlm.nih.gov/pubmed/36518770 http://dx.doi.org/10.3389/fimmu.2022.1021481 |
work_keys_str_mv | AT massetchristophe casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT dantaljacques casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT soulilloujeanpaul casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT walencikalexandre casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT delbosflorent casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT brouardsophie casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT giralmagali casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients AT casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients |